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Abstract Tail-anchored proteins are inserted into intracellular
membranes via a C-terminal transmembrane domain. The
topology of the protein is such that insertion must occur post-
translationally, since the insertion sequence is not available for
membrane insertion until after translation of the tail-anchored
polypeptide is completed. Here, we show that the targeting
information in one such tail-anchored protein, translocase in the
outer mitochondrial membrane 22, is contained in a short region
flanking the transmembrane domain. An equivalent region is
sufficient to specify the localisation of Bcl2 and SNARE proteins
to the secretory membranes. We discuss the targeting process for
directing members of this protein family to the secretory and
mitochondrial membranes in vivo.
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1. Introduction
Tail-anchored proteins are displayed on the cytosolic sur-
face of membranes by virtue of a single, carboxy-terminal
transmembrane domain. This class of membrane proteins in-
cludes most of the SNAREs involved in vesicle-mediated
transport and many of the key proteins regulating pro-
grammed cell death [1^3]. Studies on the targeting of
SNAREs to their respective membranes suggest a model
whereby the nascent SNARE polypeptides would be synthes-
ised in the cytosol, inserted into the endoplasmic reticulum
and subsequently sorted to the Golgi, vacuole or plasma
membrane [4^6]. Insertion of SNAREs into the endoplasmic
reticulum must be a post-translational process, since the mem-
brane anchor is the ¢nal segment of the polypeptide and this
segment would have to leave the ribosome in order to insert
into the target membrane.
Recently, it has become clear that several proteins found in
the mitochondrial outer membrane are also tail-anchored pro-
teins. These include translocase in the outer mitochondrial
membrane (Tom) 5 [7], Tom6 [8] and Tom22 [9,10], all of
which are components of the Tom complex. The insertion
of the SNAREs into the membranes of the secretory system
is mediated by interaction with protein components of the
endoplasmic reticulum and includes at least one ATP-depend-
ent reaction [4]. Similarly, insertion of Tom22 into the mito-
chondrial outer membrane is probably mediated by the Tom
complex [11]. The fact that tail-anchored proteins themselves
are required for vesicle targeting and in protein targeting to
mitochondria underscores that the localisation of this class of
proteins must be precise and tightly regulated. We are work-
ing to understand the initial sorting steps that ensure delivery
of the various tail-anchored proteins from the ribosome to
their target membrane.
At some stage during or soon after translation, the poly-
peptide chain must be speci¢cally targeted to the secretory
membranes (in the case of the SNARE proteins) or the mi-
tochondria (in the case of Tom22 and the other tail-anchored
Tom proteins). In order to de¢ne the sorting information
required to direct tail-anchored proteins to the correct intra-
cellular membrane, we constructed a series of fusion proteins
with the green £uorescent protein (GFP) from Aequoria vic-
toria. The carboxy-terminal region of each of the tail-anch-
ored proteins tested, including the transmembrane segment
and up to 13 £anking amino acids, is necessary and su⁄cient
to direct correct intracellular targeting in vivo.
2. Materials and methods
2.1. Plasmid constructs
All GFP-tagged protein constructs were based on the centromeric
plasmid p416MET25 (a kind gift from Johannes Hegemann) that
carries the GFP(S65T) isoform. The open reading frame from
the Bcl2 cDNA was ampli¢ed with the primers 5P-GACTAGA-
TCTGCGCACGCTGGGAGAAC-3P and 5P-GACTGAATTCTCA-
CTTGTGGCCCAGATAG-3P into the BglII/EcoRI site of the expres-
sion plasmid. GFP-synaptobrevin was constructed by ampli¢cation
of the entire encoding region of human synaptobrevin 1A from
pAct-VAMP-1A [17] with 5P-GACTAGATCTTCTGCTCCAGCT-
CAGC-3P and 5P-GACTGAATTCTTTCAAGTAAAAAAGTAGAT-
TAC-3P into the same vector. The open reading frame from the
TOM22 gene was ampli¢ed from yeast genomic DNA with the pri-
mers 5P-GGC CGG GAT CCA TGG TCG AAT TAA CTG-3P and
5P-GGG GCG AAT TCC CTA CTT CAT AAG TAT AGA TAA
GGA TAG TGG-3P and cloned into the yeast expression vector. The
C-terminal trans domain of Tom22 is a receptor-like domain in the
intermembrane space, but does not include targeting information [13^
16]. We made use of the tom22-9 allele, which lacks this small intra-
mitochondrial domain, but duplicate deletion constructs made with
the intermembrane space domain intact gave identical results for tar-
geting and complementation of the vtom22 phenotype.
GFP-Tom22-bcl was constructed by amplifying a DNA fragment
encoding the transmembrane tail from Bcl2 (amino acid sequence
F210^K239) with oligonucleotide primers 5P-GGGCGAGATCTC-
CATGGTTTGATTTCTCCTGGCTG-3P and 5P-CGCTCGAATTC-
TCACTTGTGGCCCAGATAGG-3P into the BglII/EcoRI site of
the expression plasmid encoding a GFP-Tom22(M1^A91) fusion.
GFP-Tom22-syn was constructed by ampli¢cation of amino acids
K93^T118 of human synaptobrevin 1A from pAct-VAMP-1A [17] with
5P-GATCGGATCCAAAAACTGCAAGATGATGAT-3P and 5P-G-
ACTGAATTCTTTCAAGTAAAAAAGTAGATTAC-3P and cloned
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into the BglII/EcoRI site of the expression plasmid encoding a GFP-
Tom22(M1^A91) fusion.
To construct a version of GFP targeted to the lumen of the endo-
plasmic reticulum (p416MET25sec), the S65T version of GFP was
ampli¢ed by PCR using an oligonucleotide primer that modi¢ed the
open reading frame to introduce a sequence encoding the amino acids
RSRAHDEL immediately before the stop codon. A BglII-BamHI
fragment of genomic DNA from the 5P end of the yeast gene
YIL169c was cloned immediately upstream of the GFP open reading
frame. This DNA fragment encodes the ¢rst 48 amino acids of the
protein encoded by YIL169c, which functions as a secretion sequence
(T. Beilharz, S. Gratzer and T. Lithgow, unpublished).
2.2. Yeast strains, culture and microscopy
Freshly transformed wild-type cells (JK9-3d: Mata/MatK, ura3/
ura3, leu2/leu2, his4/his4, trp1/trp1) were grown on synthetic glucose
media without uracil until the midlog phase in preparation for micros-
copy and observed with an Olympus BX50 microscope. Vital staining
with Mitotracker and Arg-CMAC was according to the suppliers
protocol (Molecular Probes).
Each of the various GFP-Tom22 constructs were transformed into
the heterozygous diploid YTJB74 to test for complementation.
YTJB74 is isogenic to JK9-3d and was derived by replacing one
copy of the TOM22 gene with the auxotrophic marker LEU2, as
previously described [10]. After sporulation and dissection of the
transformed YTJB74, only the plasmids encoding the full-length
GFP-Tom22 could readily complement LEU2 : :tom22 haploid proge-
ny. The isogenic vegd2 diploid strain YRLG1 (Mata/MatK, ura3/ura3,
leu2/leu2, his3/his3, trp1/trp1, ade2/ade2, egd2 : :ADE2/EGD2) has been
described previously [12].
Subcellular fractionation was as previously described [18], but cells
were grown on semi-synthetic medium without uracil to select for
plasmid-based expression. Under these conditions, there is some con-
tamination of the mitochondria by endoplasmic reticulum even after
puri¢cation of the organelles on Nycodenz gradients bu¡ered to pH
6.0.
Yeast cells were labelled with [35S]methionine (NEN, DuPont) as
previously described [19].
3. Results
The TOM22 gene of yeast encodes a 17 kDa polypeptide,
where a carboxy-terminal domain spans the mitochondrial
outer membrane and an amino-terminal domain of about 13
kDa is exposed to the cytosol [10,13^16]. Fusion of GFP to
the amino-terminus of Tom22 yields the bright £uorescence
characteristic of mitochondrial staining (Fig. 1A), indistin-
guishable from the staining obtained when untransformed
cells were incubated with Mitotracker (Fig. 1D). Similarly,
expression of GFP fusions incorporating the mammalian
tail-anchored proteins synaptobrevin and Bcl2 were measured.
Fig. 1B shows the SNARE protein synaptobrevin localised to
the vacuole in living yeast cells, which can be recognised as an
apparent depression in the Nomarski view of the cells (upper
panel) and can be speci¢cally stained with the proteolytically
activated dye Arg-CMAC (Fig. 1E). The GFP-Bcl2 fusion
protein is localised to the endoplasmic reticulum, which in
yeast corresponds to predominantly perinuclear staining,
with the nucleus situated beside the vacuole (Fig. 1C). The
localisation of GFP-Bcl2 is indistinguishable from the local-
isation of GFP carrying an amino-terminal signal sequence
and carboxy-terminal HDEL sequence (Fig. 1F).
Fig. 1. GFP-tail anchor fusion proteins can be targeted to distinct intracellular membranes. Wild-type yeast cells transformed with a plasmid
encoding (A) GFP-Tom22, (B) GFP-synaptobrevin or (C) GFP-Bcl2 and viewed with Nomarski optics (upper panels) or £uorescence micros-
copy (lower panels). (D) Wild-type yeast cells were incubated with Mitotracker for £uorescent staining of mitochondria. (E) Wild-type yeast
cells incubated with Arg-CMAC for £uorescent staining of vacuoles. (F) Wild-type yeast cells transformed with a plasmid encoding GFP with
a N-terminal signal sequence and C-terminal HDEL sequence to observe the endoplasmic reticulum.
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At least three proteins, Tom5, Tom6 and Tom22, are pre-
dicted to be tail-anchored in the mitochondrial outer mem-
brane [7^10], though none of these proteins shares an obvious
sequence similarity and none carries classical basic amphi-
pathic targeting sequences found on most mitochondrial pre-
cursor proteins. In order to de¢ne the region of Tom22 re-
sponsible for targeting the mitochondria, we fused discrete
regions of Tom22 to GFP and expressed the proteins in yeast.
Tom22 is targeted exclusively to the mitochondria and is func-
tional in the outer membrane. A GFP-Tom22 fusion protein
is inserted into the mitochondrial outer membrane and com-
plements the lethal defects in vtom22 cells, demonstrating that
the fusion protein is correctly integrated and functional within
the Tom complex (Fig. 2A). The smallest deletion mutant we
constructed, Tom22(v1^65), fails to complement the vtom22
cells, supporting suggestions that this region of the protein is
essential for the Tom22 function [13,20,21].
The failure of Tom22(v1^65) to complement vtom22 cells is
not due to mislocalisation of the fusion protein, since trunca-
tion of up to 85 amino acids from the amino-terminus of
Tom22 did not diminish targeting to the mitochondria (Fig.
2B). The remaining 13 amino acids of Tom22 £anking the
transmembrane domain specify delivery of the fusion to the
mitochondria. However, the transmembrane domain alone
cannot mediate targeting of GFP to the mitochondria: cells
expressing the Tom22(v1^95) fusion protein show only a very
weak £uorescence through the cytosol (Fig. 2C) and the fu-
sion protein is degraded more rapidly than GFP-Tom22 as
judged by pulse-chase analysis (Fig. 2D, E). Precise deletion
of the predicted transmembrane region leaves GFP-
Fig. 2. The targeting information in Tom22 is associated with the tail domain. (A) To measure complementation, TOM22/vtom22 yeast mu-
tants were transformed with a plasmid encoding GFP-Tom22 or GFP-Tom22(v1^65), induced to sporulate and haploid progeny dissected. The
products of four tetrads from each strain are shown. (B) Various truncation mutants of Tom22. Localisation of GFP-Tom22 domain constructs
was assayed by £uorescence microscopy in living cells. Tetrad analysis revealed that none of the deletion constructs can complement the fatal
defects of vtom22 yeast mutants. (C) The amino acid sequence of two of the constructs, GFP-Tom22(v1^85) and GFP-Tom22(v1^95). The
transmembrane domain of Tom22 (underlined) is predicted to begin at Leu98 or Ala99. Fluorescent micrographs of yeast cells expressing the
full-length and truncated fusion proteins are shown. (D) Yeast cells expressing either GFP-Tom22 (b) or GFP-Tom22(v1^95) (a) were incu-
bated with [35S]methionine for 15 min and then transferred to medium containing unlabelled methionine for the indicated times (min). After
immunoprecipitation with anti-GFP antibodies and protein A-Sepharose, samples were analysed by SDS-PAGE and phosphorimaging. (E) For
the cells expressing GFP-Tom22(v1^95), the protein turnover is compared to the relatively stable soluble protein glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). The samples were split in half at each timepoint of the chase and analysed by immunoprecipitation with anti-GFP
antibodies or anti-GAPDH antibodies. The recovery of the relatively stable GAPDH serves as the internal control for protein synthesis and re-
covery from the transformed yeast.
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Tom22(v98^152) distributed throughout the cytoplasm (Figs.
2B and 3B). We conclude that the transmembrane domain
plus 13 amino acids of the £anking sequence represent su⁄-
cient targeting information for this mitochondrial tail-anch-
ored protein.
To test whether there is dominant mitochondrial targeting
information in the cytoplasmic domain of Tom22, fusion con-
structs were made between the extramembrane domain of
Tom22 (including the £anking region up to and including
A91, but not the transmembrane region) and the carboxy-ter-
minal region of either Bcl2 or synaptobrevin (see Section 2 for
details). Fig. 3 shows that the carboxy-terminal 26 amino acid
residues from synaptobrevin or the carboxy-terminal 33 ami-
no acid residues from Bcl2 are su⁄cient to relocate the amino-
terminal region of Tom22 from the mitochondria to the mem-
brane of the vacuole or endoplasmic reticulum, respectively.
Two pieces of evidence further support the non-mitochondrial
localisation. Firstly, the Tom22 fusions fail to complement the
defects of vtom22 yeast mutants (data not shown, see Section
2). Secondly, subcellular fractionation also shows that the
GFP-Tom22-bcl construct has an identical localisation to
GFP-Bcl2 (Fig. 3C and D), the microsomal fraction is en-
riched for the endoplasmic reticulum protein Kar2 and also
for GFP-Bcl2. Although in mammalian cells a population of
Bcl2 is also found in the mitochondria [22,23], the small
amount of Bcl2 (and Tom22*-bcl) present in the yeast mito-
chondria is easily explained by the minor contamination of
mitochondria with endoplasmic reticular membranes. The tar-
geting regions from the Tom22-tom and Tom22-bcl fusion
proteins are shown in Fig. 3E.
Fig. 3. The amino-terminal domain of Tom22 does not in£uence protein targeting. (A) Plasmid-based constructs expressing fusion proteins in
which the entire cytosolic domain of Tom22 has been fused to the £anking region of synaptobrevin (GFP-Tom22-syn), Bcl2 (GFP-Tom22-bcl),
Tom22 (GFP-Tom22-tom) or no £anking region (GFP-Tom22*, this represents Tom22v98^152) were transformed into wild-type yeast cells and
the localisation of the GFP fusion proteins was determined by £uorescence microscopy. (B) Fluorescence micrographs of each of the fusion
constructs. (C) Subcellular fractionation of cells expressing GFP-Bcl2. Immunoblotting of mitochondria (lane 1) and microsomal membranes
(lane 2) with antisera recognising the mitochondrial protein cytochrome b2 and Kar2, which is localised to the endoplasmic reticulum, reveal
slight contamination of the mitochondria with membranes from the endoplasmic reticulum. (D) Cells expressing GFP-Tom22*-bcl were fractio-
nated into mitochondria (lane 1) and microsomes (lane 2) and analysed by immunoblotting with antisera to GFP, cytochrome b2 and Kar2p.
(E) Sequence alignment of Tom22-tom and Tom22-bcl. The sequence in common (bold) extends to A91 of Tom22.
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4. Discussion
4.1. Synthesis and targeting of tail-anchored proteins
Given that protein folding occurs co-translationally in vivo
[25], the amino-terminal domains of tail-anchored proteins
should be able to fold even before the carboxy-terminal trans-
membrane domain leaves the ribosome. Since the targeting
information in these tail-anchored proteins is at the car-
boxy-terminus, their insertion into the target membrane
must occur post-translationally.
The nascent polypeptide-associated complex (NAC) is a
ribosome-associated factor and yeast vegd2 mutants, lacking
the NAC function, are defective in the targeting of GFP fu-
sion proteins bearing N-terminal signal sequences to both the
endoplasmic reticulum and mitochondria [12,24]. We also ¢nd
that vegd2 mutants show an accumulation of tail-anchored
proteins in the cytoplasm, GFP-Tom22, GFP-Bcl2 and
GFP-synaptobrevin accumulate throughout the cytosol of
cells lacking NAC (data not shown). Thus, even though the
insertion of tail-anchored proteins into their target membrane
must be a post-translational process, co-translational events
e¡ect the e⁄ciency of targeting to the mitochondria and other
organelles in vivo.
This suggests two possible models for the targeting of tail-
anchored proteins in vivo. In the scenario depicted in Fig. 4A,
ribosomes synthesising the polypeptide to be inserted would
be pre-positioned at the target membrane and as the carboxy-
terminal targeting domain leaves the ribosome, it could be
recognised by membrane-located components (X) and then
inserted into the membrane. However, we favour the second
scenario (Fig. 4B) where a soluble targeting factor (X) is re-
cruited to the nascent polypeptide during the synthesis on free
ribosomes, to maintain the tail-anchored protein in a soluble
form prior to insertion into the target membrane. In cells
lacking NAC, the targeting e⁄ciency is decreased either be-
cause NAC is required directly for targeting factor binding or
because the polypeptides made on ribosomes lacking NAC
have folding defects that indirectly e¡ect targeting.
The crystal structure and NMR analysis of BclXL, a close
paralog of Bcl2, reveal a compact, globular, amino-terminal
domain de¢ned by residues 1^203, with the subsequent 13
amino acids (S204^T218) disordered in the crystal structure
and shown to be highly £exible by NMR [26]. This segment
corresponds to the £anking region we have de¢ned as being
necessary and su⁄cient for targeting Bcl2 to the endoplasmic
reticulum in yeast. We anticipate that targeting factors would
bind this £exible £anking domain co-translationally, shielding
the emergent hydrophobic carboxy-terminal segment from the
cytosol until the protein can be correctly positioned in the
target membrane. We suggest that the targeting of other
tail-anchored proteins like Tom22 and the SNAREs would
also be initiated on the ribosome.
4.2. The sorting sequence and the import sequence in Tom22
In vitro assays using either isolated mitochondria or puri-
¢ed outer membranes revealed what might be called an ‘in-
sertion sequence’ in the cytoplasmic domain of Tom22: dele-
tion of discrete sequences anywhere between residues 45^75 of
the Neurospora crassa isoform (corresponding to residues 57^
82 from Saccharomyces cerevisiae) dramatically reducing the
correct assembly of Tom22 into the oligomeric Tom complex
[11]. Our observation that Tom22(v1^65) cannot complement
the phenotype of vtom22 yeast mutants is in accord with these
previous ¢ndings in N. crassa.
However, the in vivo data presented here show that both
Tom22(v1^65) and Tom22(v1^85) are still delivered to the
mitochondria in intact cells. Reconciling this data with the
previous work undertaken with isolated mitochondria [11]
suggests that targeting from the ribosome to mitochondria is
an independent process from assembly into the outer mem-
brane. Each process would be promoted by independent tar-
geting signals and insertion signals. When the £anking region
(corresponding to amino acids T84^A91) is deleted, it prevents
targeting to the mitochondria in vivo, but if equivalent pro-
teins are synthesised in vitro, they can be assembled into the
Tom complex of isolated mitochondria [11]. Taken together,
the data gathered in vitro and in vivo are complimentary and
are best described by the import model presented in Fig. 4B.
4.3. A consensus for targeting sequences?
While we have identi¢ed the region containing the mito-
chondrial targeting information in Tom22, there is no obvious
sequence similarity to the corresponding regions of the other
mitochondrial tail-anchored proteins Tom5 or Tom6. Simi-
larly, our preliminary sequence analysis of the corresponding
region of SNARE proteins targeted to the secretory mem-
branes has not revealed any obvious common features (data
not shown).
Targeting factors might recognise and bind the £anking
region alone or the £anking region might dictate a polypep-
tide structure in the more distal hydrophobic segment. One
approach to precisely de¢ne the consensus sequence for tail-
anchored protein sorting is through extensive mutagenesis to
try to switch the localisation from the secretory to mitochon-
drial membranes or vice versa. However, our initial studies
suggest that tail-anchored proteins not e¡ectively targeted to
Fig. 4. Model describing the co-translational events that might in£u-
ence the e⁄ciency of tail-anchored protein targeting. As the C-ter-
minal targeting sequence emerges from the ribosome, it would be-
come available to be recognised by speci¢c targeting factors (X)
that might be located (A) on the surface of the mitochondria or (B)
in the cytosol. Model A would require that the translating ribosome
has been pre-localised to the mitochondria. Model B is supported
by the observations that soluble forms of tail-anchored proteins are
observed for mutants carrying small deletions in the targeting se-
quence and that the localisation of chimaeric constructs is deter-
mined solely by the ¢nal sequences in the polypeptide. In both mod-
els, insertion of the tail-anchored protein in its target membrane is
a post-translational process.
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their correct membrane in wild-type yeast cells remain in the
soluble phase of the cytoplasm and are rapidly degraded. The
alternative approach is to identify speci¢c targeting factors
from the cytosol, to address the nature of the sorting infor-
mation by solving the three-dimensional structure of the se-
quences bound to these cognate factors.
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